Serum VEGF and bFGF concentrations and components of the International Prognostic Index in multivariate analyses
| Factor . | Relative risk (RR, eβ) . | 95% CI for RR . | P . |
|---|---|---|---|
| IPI | |||
| ≥2 | 6.34 | 3.56-11.32 | <.0001 |
| Serum VEGF and bFGF at diagnosis both ≥ highest quartiles | 2.90 | 1.56-5.40 | .0008 |
| WHO performance status ≥2 | 2.74 | 1.60-4.68 | .0002 |
| Age at diagnosis | |||
| >60 y | 2.49 | 1.56-3.97 | .0001 |
| Serum LDH at diagnosis | |||
| Abnormal | 2.46 | 1.53-3.96 | .0002 |
| Ann Arbor stage | |||
| ≥III | 2.29 | 1.42-3.70 | .0007 |
| No. extranodal tumor sites | |||
| >1 | 1.81 | 0.90-3.63 | .094 |
| Serum bFGF at diagnosis | |||
| ≥5.5 pg/mL (highest quartile) | 2.02 | 1.24-3.28 | .0049 |
| Serum VEGF at diagnosis | |||
| ≥462 pg/mL (highest quartile) | 1.83 | 1.10-3.02 | .019 |
| Factor . | Relative risk (RR, eβ) . | 95% CI for RR . | P . |
|---|---|---|---|
| IPI | |||
| ≥2 | 6.34 | 3.56-11.32 | <.0001 |
| Serum VEGF and bFGF at diagnosis both ≥ highest quartiles | 2.90 | 1.56-5.40 | .0008 |
| WHO performance status ≥2 | 2.74 | 1.60-4.68 | .0002 |
| Age at diagnosis | |||
| >60 y | 2.49 | 1.56-3.97 | .0001 |
| Serum LDH at diagnosis | |||
| Abnormal | 2.46 | 1.53-3.96 | .0002 |
| Ann Arbor stage | |||
| ≥III | 2.29 | 1.42-3.70 | .0007 |
| No. extranodal tumor sites | |||
| >1 | 1.81 | 0.90-3.63 | .094 |
| Serum bFGF at diagnosis | |||
| ≥5.5 pg/mL (highest quartile) | 2.02 | 1.24-3.28 | .0049 |
| Serum VEGF at diagnosis | |||
| ≥462 pg/mL (highest quartile) | 1.83 | 1.10-3.02 | .019 |